Monday, November 19, 2018

Investigational Compound from Chinese Tree Bark Shows Potential as Treatment for Pancreatic Cancer

A new compound found in the bark of a rare Chinese tree, called FL118, has powerful anticancer properties and a low toxicity profile. This is what researchers at Roswell Park Comprehensive Cancer Center observed in a study funded by grants from the National Cancer Institute and by donations to Roswell Park The results of their study outlining the effect...

Oral Sores and Cancer Treatment

“When I was diagnosed with breast cancer in 2003, I was ready to fight for my life, but I didn’t know about mouth sores or how hard they would make it for me.” Alex F. developed white, pus-filled sores only one week after starting on chemotherapy. ‘Oh my gosh! It was so difficult to chew and swallow. Everything I ate...

First-line Treatment with Pembrolizumab

Results of a phase III clinical trial called KEYNOTE-189, presented at the Annual Meeting of the American Association for Cancer Research (AACR), held April 14-18., 2018, shows that patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer or NSCLC who received pembrolizumab (Keytruda®; Merck Oncology; previously known as MK-3475), a IgG4 humanized antibody used as programmed death 1...

First Patients Enrolled in Landmark Lung Cancer Tri-Therapy Clinical Trial

As part of an international collaboration that looks to transform care for lung cancer patients the first patients have been enroll in a new cancer study at Avera, an integrated health system comprised of more than 330 locations in 100 communities in a five-state region offering a full continuum of care is offered through 32 hospitals, 200+ clinics, retirement communities,...

Charitable Efforts Know No Boundaries When Helping the Underserved— Stakeholders Strive to Continue Access to Breast Cancer Treatment in Arizona

When a steady, relied-upon source of funding was ending, a public-private coalition of concerned stakeholders was created in Arizona to ensure that certain critical health care services could be continued. In June, Susan G. Komen’s Arizona affiliate announced via a letter posted online that “based on financial challenges and current downward trends in overall fundraising and event participation which limited...

Anti-Leukemic Activity and Safety Data for Gilteritinib in Relapsed

As published in The Lancet Oncology this week, investigational data from the Phase I/II CHRYSALIS trial studying anti-leukemic activity and tolerability of gilteritinib, also known as ASP2215 (Astellas), supports the initiation of currently enrolling pivotal phase III ADMIRAL Trial. Gilteritinib is a novel, highly selective, potent oral FLT3/AXL inhibitor with preclinical activity against FLT3-ITD activating and FLT3-D835 resistance mutations. ...

Eric Rosenthal Reports: Placing Cancer Fear in its Proper Perspective

During his first inaugural address in 1933, President Franklin D. Roosevelt famously said, “the only thing we have to fear is fear itself.” It was in the midst of the economic Depression and the newly elected president was trying to raise the hopes of a nation in despair suffering also from the throes of psychological depression. Earlier this month while attending...

Palbociclib may have Wider Applicability in Targeting Cancer

Palbociclib (Ibrance®; Pfizer) an oral agent that target cyclin-dependent kinases (CDK4 and CDK6), which appear to promote tumor cell proliferation in hormone-receptor positive breast cancer, is gaining notice for its ability to derail cancer cell growth, may also have a second application that renders it lethal to cancers carrying high levels of a certain protein, researchers at Dana-Farber Cancer...

First Immunotherapy Expected for the treatment of Malignant Pleural Mesothelioma

Accounting for approximately 80% – 90% of all mesothelioma cases, malignant pleural mesothelioma or MPM is a rare but aggressive cancer. It is usually associated with occupational exposure to asbestos fibers and develops in the thin layer of tissue surrounding the lungs known as the pleura. Following exposure, these fibers accumulate in the body which causes chronic inflammation, leading...

Encouraging Breakthrough in the Treatment of Patients with Multiple Myeloma

Excitement is growing for the treatment of patients with various forms of cancer using  immunotherapy — specific therapies that harness the power of a patient’s own immune system to combat their disease. The concept involves engineering chimeric antigen receptor T cells, also known as natural killer cells, for a specific antigen that is more prevalent in a specific disease...

Related articles